According to a recent LinkedIn post from Laplace Interventional, the company’s Laplace TTVR device was featured in a JACC: Case Reports article describing treatment of severe tricuspid regurgitation in a patient with complex anatomy. The post notes that a previously planned commercial tricuspid procedure was aborted due to insufficient right atrial height, whereas Laplace TTVR enabled a successful intervention.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post indicates that the case report described complete elimination of tricuspid regurgitation and improvements in functional status and quality of life following use of Laplace TTVR. For investors, this type of peer‑reviewed case exposure may support clinical credibility, particularly in anatomically challenging patients, and could strengthen the company’s positioning in the transcatheter tricuspid replacement segment.
While the post centers on a single case report, publication in a journal such as JACC: Case Reports may aid physician awareness and early adoption if broader clinical data eventually show consistent outcomes. If Laplace Interventional can translate these individual successes into larger clinical programs and regulatory progress, the technology could address a niche within structural heart interventions and potentially expand its addressable market.